AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (1 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

Inhibition of ALDH2 by disulfiram leads to synthetic lethality via ROS strikes twice in ARID1A-deficient cholangiocarcinoma

Tingming Lianga, Lin Jiaa, Rui Duana, Lulu Shena, Dekang Renb, Yujie Renb, Yuyang Doub, Li Guob( )
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing, Jiangsu 210023, China
Department of Bioinformatics, Smart Health Big Data Analysis and Location Services Engineering Lab of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts and Telecommunications, Nanjing, Jiangsu 210023, China
Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Genes & Diseases
Volume 10 Issue 1,
January 2023
Pages 69-71
DOI: 10.1016/j.gendis.2022.02.005

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Liang T, Jia L, Duan R, et al. Inhibition of ALDH2 by disulfiram leads to synthetic lethality via ROS strikes twice in ARID1A-deficient cholangiocarcinoma. Genes & Diseases, 2023, 10(1): 69-71. https://doi.org/10.1016/j.gendis.2022.02.005

575

Views

6

Downloads

5

Crossref

3

Web of Science

3

Scopus

0

CSCD
Published: 16 March 2022
© 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).